• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by NovoCure Limited (Amendment)

    2/9/24 6:03:23 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care
    Get the next $NVCR alert in real time by email
    SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 4 )*

                

    NovoCure Ltd.


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    G6674U108


    (CUSIP Number)

    December 29, 2023


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. G6674U108

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    Capital International Investors
    95-1411037
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 8,896,076
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 8,896,076
    8. SHARED DISPOSITIVE POWER 0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    8,896,076 Beneficial ownership disclaimed pursuant to Rule 13d-4
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.3%
    12. TYPE OF REPORTING PERSON

    IA

    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    


    Item 1.
    (a) Name of Issuer
    NovoCure Ltd.
    (b) Address of Issuer's Principal Executive Offices
    No. 4 The Forum, Grenville Street, SAINT HELIER, JE JE2 4UF, JERSEY
    Item 2.
    (a) Name of Person Filing
    Capital International Investors
    (b) Address of Principal Business Office or, if None, Residence
    333 South Hope Street, 55th Fl, Los Angeles, CA 90071
    (c) Citizenship
    N/A
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    G6674U108
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    8,896,076 **
    (b) Percent of Class:
    8.3%
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 8,896,076
    (ii) shared power to vote or to direct the vote 0
    (iii) sole power to dispose or to direct the disposition of 8,896,076
    (iv) shared power to dispose or to direct the disposition of 0
    **Capital International Investors ("CII") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CII's divisions of each of the investment management entities collectively provide investment management services under the name "Capital International Investors." CII is deemed to be the beneficial owner of 8,896,076 shares or 8.3% of the 106,861,113 shares believed to be outstanding.
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    Not Applicable
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not Applicable
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable. This schedule is not being filed pursuant to Rule 13d-1(b)(1)(ii)(J) or Rule 13d-1(d).
    Item 9. Notice of Dissolution of Group.

    Not Applicable
    Item 10. Certification.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Capital International Investors
    By: /s/ Jae Won Chung
    Date: February 07, 2024
    Name: Jae Won Chung
    Title: Vice President and Associate Counsel, Fund Business Management Group, Capital Research and Management Company

    Get the next $NVCR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVCR

    DatePrice TargetRatingAnalyst
    12/2/2024$18.00 → $30.00In-line → Outperform
    Evercore ISI
    10/16/2024$24.00 → $30.00Neutral → Buy
    H.C. Wainwright
    11/20/2023$15.00Neutral
    JP Morgan
    8/28/2023$85.00 → $25.00Buy → Neutral
    H.C. Wainwright
    8/8/2023$45.00Neutral → Overweight
    Piper Sandler
    8/4/2023$51.00Outperform
    SVB Securities
    7/31/2023$33.00Underperform → In-line
    Evercore ISI
    6/7/2023$53.00 → $46.00Underperform → Neutral
    Wedbush
    More analyst ratings

    $NVCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

      TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for patients with unresectable, locally advanced pancreatic adenocarcinoma in a Phase 3 trial The OS benefit observed with TTFields therapy is supported by significantly improved quality of life and extended pain-free survival, a key outcome for patients with pancreatic cancer Results from PANOVA-3 accepted as a late-breaking abstract for oral presentation at ASCO and simultaneous publication in the Journal of Clinical Oncology Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) and Novocure (NASDAQ:NVCR)

      5/31/25 3:08:00 PM ET
      $NVCR
      $ZLAB
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

      TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for patients with unresectable, locally advanced pancreatic adenocarcinoma in a Phase 3 trial The OS benefit observed with TTFields therapy is supported by significantly improved quality of life and extended pain-free survival, a key outcome for patients with pancreatic cancer Results from PANOVA-3 accepted as a late-breaking abstract for oral presentation at ASCO and simultaneous publication in the Journal of Clinical Oncology Novocure (NASDAQ:NVCR) announced that results from the Phase 3 PANOVA-3 tr

      5/31/25 8:00:00 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • Novocure Announces Upcoming Investor Events

      Novocure (NASDAQ:NVCR) announced today that management will participate in two upcoming investor events. PANOVA-3 Investor Event, May 31, 2025: Novocure will host investors on Saturday, May 31 at 8:00 p.m. ET / 7:00 p.m. CT in Chicago to review data from the successful Phase 3 PANOVA-3 clinical trial in unresectable, locally advanced pancreatic cancer. Novocure leadership will be joined by Vincent Picozzi, MD, MMM, medical oncologist and investigator in the PANOVA-3 trial, to review the results and address questions. To request in-person attendance, please contact investor relations at [email protected]. Jefferies Global Healthcare Conference, June 4, 2025: Ashley Cordova, Chi

      5/27/25 7:00:00 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care

    $NVCR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • October 18, 2024 - FDA Roundup: October 18, 2024

      For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

      10/18/24 4:16:25 PM ET
      $NVCR
      $BAX
      Medical/Dental Instruments
      Health Care

    $NVCR
    SEC Filings

    See more
    • NovoCure Limited filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - NovoCure Ltd (0001645113) (Filer)

      6/6/25 4:26:53 PM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • NovoCure Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - NovoCure Ltd (0001645113) (Filer)

      6/2/25 6:05:55 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • NovoCure Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - NovoCure Ltd (0001645113) (Filer)

      4/24/25 7:02:25 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care

    $NVCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Leung Gabriel was granted 11,215 units of Ordinary Shares, increasing direct ownership by 14% to 92,444 units (SEC Form 4)

      4 - NovoCure Ltd (0001645113) (Issuer)

      6/6/25 4:21:51 PM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • Director Stafford Kristin was granted 11,215 units of Ordinary Shares, increasing direct ownership by 367% to 14,269 units (SEC Form 4)

      4 - NovoCure Ltd (0001645113) (Issuer)

      6/6/25 4:20:45 PM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Madden Martin J.

      4 - NovoCure Ltd (0001645113) (Issuer)

      6/6/25 4:19:11 PM ET
      $NVCR
      Medical/Dental Instruments
      Health Care

    $NVCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • NovoCure upgraded by Evercore ISI with a new price target

      Evercore ISI upgraded NovoCure from In-line to Outperform and set a new price target of $30.00 from $18.00 previously

      12/2/24 6:59:42 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • NovoCure upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded NovoCure from Neutral to Buy and set a new price target of $30.00 from $24.00 previously

      10/16/24 7:29:57 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • JP Morgan resumed coverage on NovoCure with a new price target

      JP Morgan resumed coverage of NovoCure with a rating of Neutral and set a new price target of $15.00

      11/20/23 7:51:08 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care

    $NVCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by NovoCure Limited

      SC 13G/A - NovoCure Ltd (0001645113) (Subject)

      7/10/24 1:14:41 PM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by NovoCure Limited

      SC 13G/A - NovoCure Ltd (0001645113) (Subject)

      7/8/24 4:32:39 PM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by NovoCure Limited (Amendment)

      SC 13G/A - NovoCure Ltd (0001645113) (Subject)

      2/13/24 5:09:51 PM ET
      $NVCR
      Medical/Dental Instruments
      Health Care

    $NVCR
    Leadership Updates

    Live Leadership Updates

    See more
    • Novocure Appoints Christoph Brackmann as Chief Financial Officer

      Novocure (NASDAQ:NVCR) announced today that Christoph Brackmann has been appointed as the company's next Chief Financial Officer (CFO). Mr. Brackmann will join Novocure immediately as a Senior Financial Advisor and will transition to the role of CFO on January 1, 2025 when current CFO, Ashley Cordova, becomes CEO. Mr. Brackmann joins Novocure from Moderna, Inc. where he served as Senior Vice President of Finance since 2019. While at Moderna he established and built the finance team and oversaw the rapid expansion of the organization during the COVID-19 pandemic. "The addition of Christoph to our Novocure executive team comes at a pivotal time for the organization as we expand our product

      10/30/24 7:02:00 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care
    • Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors

      Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns

      10/18/24 9:00:00 AM ET
      $ENV
      $LH
      $MASI
      $MSCI
      Business Services
      Consumer Discretionary
      Medical Specialities
      Health Care
    • Novocure Announces Planned CEO Transition

      After 22 years as CEO, Asaf Danziger to retire at year end, will be succeeded by current CFO Ashley Cordova Wilco Groenhuysen to step down after 12 years as COO, Mukund Paravasthu current Senior Vice President, Product Development to transition to COO Novocure (NASDAQ:NVCR) announced today that Chief Executive Officer (CEO), Asaf Danziger, will retire at year-end 2024 and Novocure's Chief Financial Officer (CFO), Ashley Cordova, will succeed him as the company's next CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903420700/en/Asaf Danziger, Chief Executive Officer (Photo: Business Wire) Mr. Danziger, who has served a

      9/3/24 7:00:00 AM ET
      $NVCR
      Medical/Dental Instruments
      Health Care